Slide 1: Slide footer goes here if required
Slide footer goes here if required 1
Slide 2: 3rd Quarter 2023 Earnings Call
3 Quarter 2023 Earnings Call October 17, 2023 Johnson&Johnson
Slide 3: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business st
Slide 4: Strategic Partnerships, Collaborations & Licensing Arrangements
Strategic Partnerships, Collaborations & Licensing Arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Slide 5: Agenda
Agenda @ Enterprise Highlights ® Sales Performance and Earnings Review (6) Capital Allocation and Guidance ® aa John Reed, M.D., Ph.D. Executive Vice President, Innovative Medicine, R&D Joseph J. Wolk Executive Vice President, Chief Financial Officer Joaquin Duato Chairman of the Board and Chief Exe
Slide 6: Quarter 2023 Sales
3 Quarter 2023 Sales % CHANGE Dollars in Billions Regional Sales Results! Q3 2023 Q3 2022 Reported Operational? U.S. $12.0 $10.8 11.1% 11.1% Europe 47 4.8 (2.4) (7.8) Western Hemisphere (ex US.) 1.2 1 10.5 12.8 Asia-Pacific, Africa EL) 3.3 48 9.4 International 9.4 9.2 1.6 0.7 Worldwide (WW) $21.4 $2
Slide 7: 3rd Quarter 2023 Financial Highlights
3" Quarter 2023 Financial Highlights’ Dollars in Billions, except EPS Reported %; Operational %2 Sales GAAP Earnings $21.4 $20.0 Q3 2023 Q3 2022 Q3 2023 = Q32022 6.8%; 6.4% 0.0% Adjusted Earnings? $6.8 $5.9 Q3 2023 Q3 2022 14.1% SR Resutsheve been recast to reflect the contiing operations of Johnson
Slide 8: Operational Growth
• • • • ■ ■ Operational Growth • • • • • • • • • • •
Slide 9: Operational Growth
• • • ■ ■ Operational Growth • • • • • • • • • • •
Slide 10: Condensed Consolidated Statement of Earnings Quarter 2023
Condensed Consolidated Statement of Earnings 3 Quarter 2023 2023 2022 x Increase (Unaudited; Dollar and Shares in Millions Except Per Share Figures) moan sbto Sates moan sbto Sates (Decrease) Sales to customers $21,351 400.0 $19,996 400.0 68 Cost of products sold 6,606 30.9 6,172 30.9 7.0 Gross Prof
Slide 11: Adjusted Income by Segment Quarter 2023
Adjusted Income by Segment” 3 Quarter 2023 $8.0B % to Sales Innovative Medicine* 45.4% 41.4% MedTech 24.7% 25.0% Total 37.6% 35.3% || Innovative Medicine* (8) MedTech HE Expenses Not Allocated to Segments 2023° 2022 lation schedules on the Investor Relations section of the company's wabsite
Slide 12: Joseph J. Wolk
Joseph J. Wolk Executive Vice President, Chief Financial Officer
Slide 13: Kenvue Separation Highlights
$13.2B Cash Proceeds Kenvue Separation Highlights 191mm Share Reduction ~180mMM Shares of KVUE Stock Retained
Slide 14: Notable Announcements in 3rd Quarter 2023
Notable Announcements in 3rd Quarter 2023 Innova ie Medi Regulatory: USS. FDA Approves TALVEY (talquetamab-tgvs),a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma European Commission Approves TALVEY (talquetamab), Janssen’s Novel Bispecific Th
Slide 15: Capital Allocation Strategy
Capital Allocation Strategy Dollars in Billions Q3 2023 Capital Allocation Cash and Marketable $24 HIGHER Securities PRIORITY I . . Debt ($30) Organic growth business needs I Net Debt! ($6) Free cash flow? Free Cash Flow2? ~$12 Q3 2023: ; Competitive dividends $3.4B invested in R&D Investment in M&A
Slide 16: 2023 P&L Guidance
2023 P&L Guidance' Due to continued strong performance, raising and tightening top- and bottom-line guidance Adjusted Operational Sales?3.” Operational Sales?” Estimated Reported Sales4” Adjusted Pre-Tax Operating Margin®.© Net Other Income® Net Interest Expense / (Income) Effective Tax Rate> Adjust
Slide 17: 2024 Considerations
2024 Considerations J&J Innovative Medicine MedTech Enterprise and P&L Confident in our ability to deliver growth from key brands and continued progress from newly launched products Continued advances in pipeline, data readouts, and approvals Stelara EU COM expiry mid-2024; do not expect biosimilar
Slide 18: Reminder: Save the Date, Enterprise Business Review
Reminder: Save the Date Introducing Our First Ever... Enterprise Business Review Focused on the New Johnson & Johnson Highlighting both the Innovative Medicine & MedTech businesses Tuesday, December 5, 2023 New York Stock Exchange Johnson&Johnson
Slide 19: John Reed, M.D., Ph.D.
¢ John Reed, M.D., Ph.D. Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman of the Board and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer alq Ahmet Tezel, Ph.D. Erik Haas Jessica Moore Company Group Chairman, Worldwide Vice President
Slide 20: Johnson&Johnson
Johnson&Johnson
Slide 21: Johnson & Johnson Innovative Medicine Pipeline – Key Events in 2023
Johnson & Johnson Innovative Medicine Pipeline – Key Events in 2023* POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA Sum Sumof of Program Region Check Change Change Change Sum Sum Phase of of Program Region Check III Change Change Change Phase I/II P US AKEEGA (niraparib/